FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794654744> ?p ?o ?g. }

• W2794654744 endingPage "433" @default.
• W2794654744 startingPage "423" @default.
• W2794654744 abstract "Background Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, fatal motor neuron disease with a variable natural history. There are no accurate models that predict the disease course and outcomes, which complicates risk assessment and counselling for individual patients, stratification of patients for trials, and timing of interventions. We therefore aimed to develop and validate a model for predicting a composite survival endpoint for individual patients with ALS. Methods We obtained data for patients from 14 specialised ALS centres (each one designated as a cohort) in Belgium, France, the Netherlands, Germany, Ireland, Italy, Portugal, Switzerland, and the UK. All patients were diagnosed in the centres after excluding other diagnoses and classified according to revised El Escorial criteria. We assessed 16 patient characteristics as potential predictors of a composite survival outcome (time between onset of symptoms and non-invasive ventilation for more than 23 h per day, tracheostomy, or death) and applied backward elimination with bootstrapping in the largest population-based dataset for predictor selection. Data were gathered on the day of diagnosis or as soon as possible thereafter. Predictors that were selected in more than 70% of the bootstrap resamples were used to develop a multivariable Royston-Parmar model for predicting the composite survival outcome in individual patients. We assessed the generalisability of the model by estimating heterogeneity of predictive accuracy across external populations (ie, populations not used to develop the model) using internal–external cross-validation, and quantified the discrimination using the concordance (c) statistic (area under the receiver operator characteristic curve) and calibration using a calibration slope. Findings Data were collected between Jan 1, 1992, and Sept 22, 2016 (the largest data-set included data from 1936 patients). The median follow-up time was 97·5 months (IQR 52·9–168·5). Eight candidate predictors entered the prediction model: bulbar versus non-bulbar onset (univariable hazard ratio [HR] 1·71, 95% CI 1·63–1·79), age at onset (1·03, 1·03–1·03), definite versus probable or possible ALS (1·47, 1·39–1·55), diagnostic delay (0·52, 0·51–0·53), forced vital capacity (HR 0·99, 0·99–0·99), progression rate (6·33, 5·92–6·76), frontotemporal dementia (1·34, 1·20–1·50), and presence of a C9orf72 repeat expansion (1·45, 1·31–1·61), all p<0·0001. The c statistic for external predictive accuracy of the model was 0·78 (95% CI 0·77–0·80; 95% prediction interval [PI] 0·74–0·82) and the calibration slope was 1·01 (95% CI 0·95–1·07; 95% PI 0·83–1·18). The model was used to define five groups with distinct median predicted (SE) and observed (SE) times in months from symptom onset to the composite survival outcome: very short 17·7 (0·20), 16·5 (0·23); short 25·3 (0·06), 25·2 (0·35); intermediate 32·2 (0·09), 32·8 (0·46); long 43·7 (0·21), 44·6 (0·74); and very long 91·0 (1·84), 85·6 (1·96). Interpretation We have developed an externally validated model to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS. This model could be applied to individualised patient management, counselling, and future trial design, but to maximise the benefit and prevent harm it is intended to be used by medical doctors only. Funding Netherlands ALS Foundation. Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, fatal motor neuron disease with a variable natural history. There are no accurate models that predict the disease course and outcomes, which complicates risk assessment and counselling for individual patients, stratification of patients for trials, and timing of interventions. We therefore aimed to develop and validate a model for predicting a composite survival endpoint for individual patients with ALS. We obtained data for patients from 14 specialised ALS centres (each one designated as a cohort) in Belgium, France, the Netherlands, Germany, Ireland, Italy, Portugal, Switzerland, and the UK. All patients were diagnosed in the centres after excluding other diagnoses and classified according to revised El Escorial criteria. We assessed 16 patient characteristics as potential predictors of a composite survival outcome (time between onset of symptoms and non-invasive ventilation for more than 23 h per day, tracheostomy, or death) and applied backward elimination with bootstrapping in the largest population-based dataset for predictor selection. Data were gathered on the day of diagnosis or as soon as possible thereafter. Predictors that were selected in more than 70% of the bootstrap resamples were used to develop a multivariable Royston-Parmar model for predicting the composite survival outcome in individual patients. We assessed the generalisability of the model by estimating heterogeneity of predictive accuracy across external populations (ie, populations not used to develop the model) using internal–external cross-validation, and quantified the discrimination using the concordance (c) statistic (area under the receiver operator characteristic curve) and calibration using a calibration slope. Data were collected between Jan 1, 1992, and Sept 22, 2016 (the largest data-set included data from 1936 patients). The median follow-up time was 97·5 months (IQR 52·9–168·5). Eight candidate predictors entered the prediction model: bulbar versus non-bulbar onset (univariable hazard ratio [HR] 1·71, 95% CI 1·63–1·79), age at onset (1·03, 1·03–1·03), definite versus probable or possible ALS (1·47, 1·39–1·55), diagnostic delay (0·52, 0·51–0·53), forced vital capacity (HR 0·99, 0·99–0·99), progression rate (6·33, 5·92–6·76), frontotemporal dementia (1·34, 1·20–1·50), and presence of a C9orf72 repeat expansion (1·45, 1·31–1·61), all p<0·0001. The c statistic for external predictive accuracy of the model was 0·78 (95% CI 0·77–0·80; 95% prediction interval [PI] 0·74–0·82) and the calibration slope was 1·01 (95% CI 0·95–1·07; 95% PI 0·83–1·18). The model was used to define five groups with distinct median predicted (SE) and observed (SE) times in months from symptom onset to the composite survival outcome: very short 17·7 (0·20), 16·5 (0·23); short 25·3 (0·06), 25·2 (0·35); intermediate 32·2 (0·09), 32·8 (0·46); long 43·7 (0·21), 44·6 (0·74); and very long 91·0 (1·84), 85·6 (1·96). We have developed an externally validated model to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS. This model could be applied to individualised patient management, counselling, and future trial design, but to maximise the benefit and prevent harm it is intended to be used by medical doctors only." @default.
• W2794654744 created "2018-04-06" @default.
• W2794654744 creator A5000073922 @default.
• W2794654744 creator A5002390430 @default.
• W2794654744 creator A5005633849 @default.
• W2794654744 creator A5008484351 @default.
• W2794654744 creator A5010017708 @default.
• W2794654744 creator A5013023361 @default.
• W2794654744 creator A5013667394 @default.
• W2794654744 creator A5018645637 @default.
• W2794654744 creator A5024570101 @default.
• W2794654744 creator A5026110715 @default.
• W2794654744 creator A5028989061 @default.
• W2794654744 creator A5030609927 @default.
• W2794654744 creator A5031372738 @default.
• W2794654744 creator A5033670047 @default.
• W2794654744 creator A5034766910 @default.
• W2794654744 creator A5035719907 @default.
• W2794654744 creator A5038119270 @default.
• W2794654744 creator A5040831166 @default.
• W2794654744 creator A5044745514 @default.
• W2794654744 creator A5044833174 @default.
• W2794654744 creator A5045232979 @default.
• W2794654744 creator A5048923862 @default.
• W2794654744 creator A5049205373 @default.
• W2794654744 creator A5049549975 @default.
• W2794654744 creator A5049896776 @default.
• W2794654744 creator A5050798393 @default.
• W2794654744 creator A5050965055 @default.
• W2794654744 creator A5053279441 @default.
• W2794654744 creator A5054947780 @default.
• W2794654744 creator A5057016612 @default.
• W2794654744 creator A5058700745 @default.
• W2794654744 creator A5061606150 @default.
• W2794654744 creator A5062143490 @default.
• W2794654744 creator A5067571282 @default.
• W2794654744 creator A5068470805 @default.
• W2794654744 creator A5068895190 @default.
• W2794654744 creator A5069816083 @default.
• W2794654744 creator A5073088894 @default.
• W2794654744 creator A5074077702 @default.
• W2794654744 creator A5075905262 @default.
• W2794654744 creator A5078835186 @default.
• W2794654744 creator A5082795436 @default.
• W2794654744 creator A5083104697 @default.
• W2794654744 creator A5086788354 @default.
• W2794654744 creator A5090456261 @default.
• W2794654744 creator A5090628289 @default.
• W2794654744 creator A5090934892 @default.
• W2794654744 date "2018-05-01" @default.
• W2794654744 modified "2023-10-11" @default.
• W2794654744 title "Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model" @default.
• W2794654744 cites W1012257715 @default.
• W2794654744 cites W1980827933 @default.
• W2794654744 cites W1981295136 @default.
• W2794654744 cites W1985299015 @default.
• W2794654744 cites W1985851580 @default.
• W2794654744 cites W1990554411 @default.
• W2794654744 cites W2005995330 @default.
• W2794654744 cites W2015589461 @default.
• W2794654744 cites W2025198514 @default.
• W2794654744 cites W2065974896 @default.
• W2794654744 cites W2095880617 @default.
• W2794654744 cites W2105100844 @default.
• W2794654744 cites W2119277569 @default.
• W2794654744 cites W2122892545 @default.
• W2794654744 cites W2126602794 @default.
• W2794654744 cites W2128030851 @default.
• W2794654744 cites W2129877998 @default.
• W2794654744 cites W2133305315 @default.
• W2794654744 cites W2135369095 @default.
• W2794654744 cites W2138207816 @default.
• W2794654744 cites W2147955864 @default.
• W2794654744 cites W2148402935 @default.
• W2794654744 cites W2155221045 @default.
• W2794654744 cites W2161938104 @default.
• W2794654744 cites W2162491525 @default.
• W2794654744 cites W2162851271 @default.
• W2794654744 cites W2164647869 @default.
• W2794654744 cites W2167702473 @default.
• W2794654744 cites W2238421080 @default.
• W2794654744 cites W2474667434 @default.
• W2794654744 cites W2491827732 @default.
• W2794654744 cites W2587456711 @default.
• W2794654744 cites W2594396441 @default.
• W2794654744 cites W2614986146 @default.
• W2794654744 cites W2913609543 @default.
• W2794654744 cites W402335930 @default.
• W2794654744 cites W4210998205 @default.
• W2794654744 cites W4233026002 @default.
• W2794654744 cites W805634547 @default.
• W2794654744 doi "https://doi.org/10.1016/s1474-4422(18)30089-9" @default.
• W2794654744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29598923" @default.
• W2794654744 hasPublicationYear "2018" @default.
• W2794654744 type Work @default.
• W2794654744 sameAs 2794654744 @default.
• W2794654744 citedByCount "302" @default.
• W2794654744 countsByYear W27946547442018 @default.

• next